Treatment of bullous impetigo and the staphylococcal scalded skin syndrome in infants

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 3, 2004, Pages 439-446

  Johnston, Graham A ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bullous impetigo; Staphylococcal exfoliative toxin; Staphylococcal scalded skin syndrome; Staphylococcus aureus

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFACLOR; CEFALEXIN; CEFOTAXIME; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CICATRIN; CLARITHROMYCIN; CYCLOSPORIN A; DICLOXACILLIN; DIGOXIN; ERYTHROMYCIN; EXFOLIATIN; FLUCLOXACILLIN; FUSIDATE SODIUM; FUSIDIC ACID; ITRACONAZOLE; LORATADINE; MIZOLASTINE; NEBACETIN; PENICILLIN G; POVIDONE IODINE; PSEUDOMONIC ACID; STAPHYLOCOCCUS TOXIN; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL ARTHRITIS; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CARRIER; BACTERIUM CULTURE; BULLOUS SKIN DISEASE; CLINICAL FEATURE; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EPIDEMIC; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HUMAN; IMPETIGO BULLOSA; INFANT; LIVER TOXICITY; NAUSEA; NOSE SMEAR; NURSERY; OBSTRUCTIVE JAUNDICE; OSTEOMYELITIS; PATHOGENESIS; PNEUMONIA; PROGNOSIS; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYMPTOMATOLOGY; TOXIC EPIDERMAL NECROLYSIS; VOMITING; WARD;

EID: 2942519525     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.3.439     Document Type: Review

References (43)

1. Resnick SD. Staphylococcal and streptococcal skin infections: pyodermas and toxin-mediated syndromes. In: Textbook of Pediatric Dermatology. Harper J, Oranje A, Prose N (Eds). Blackwell Science Ltd, Oxford, UK (2000).
2. Lee P, Zipoli M, Weinberg A, Swartz M, Johnson R. Pyodermas: Staphylococus aureus, Streptococcus and other Gram-positive bacteria. In: Fitzpatrick's Dermatology in General Medicine. Freedberg I, Eisen A, Wolff K, Austen K, Goldsmith L, Katz S (Eds). McGraw-Hill, NY, USA (2003).
3. Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19 month period. Epidemiol. Infect. 115(1), 51-60 (1995).
4. Fritsch P, Elias P. Varga J. The fate of staphylococcal exfoliatin in newborn and adult mice. Br. J. Dermatol. 95(3), 275-284 (1976).
5. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nature Med. 6(11), 1275-1277 (2000).
6. Resnick S, Fritsch P, Elias P. The staphylococcal scalded skin and toxic shock syndromes. In: Physiology, biochemistry and molecular biology of the skin. Goldsmith L (Ed.). Oxford University Press, Oxford, UK (1991).
7. Monday SR, Vath GM, Ferens WA et al. Unique superantigen activity of staphylococcal exfoliative toxins. J. Immunol. 162(8), 4550-4559 (1999).
8. Feingold DS. Staphylococcal and streptococcal pyodermas. Semin. Dermatol. 12(4), 331-335 (1993).
9. Florman A, Holzman R. Nosocomial scalded skin syndrome. Ritter's disease caused by phage group 3 Staphylococcus aureus. Am. J. Dis. Child. 134, 1043-1045 (1980).
10. Hlady WG, Middaugh JP. An epidemic of bullous impetigo in a newborn nursery due to Staphylococcus aureus: epidemiology and control measures. Alaska Med. 28(4), 99-103 (1986).
11. Hoeger PH, Elsner P. Staphylococcal scalded skin syndrome: transmission of exfoliatin-producing Staphylococcus aureus by an asymptomatic carrier. Pediatr. Infect. Dis. J. 7(5), 340-342 (1988).
12. Dancer SJ, Simmons NA, Poston SM, Noble WC. Outbreak of staphylococcal scalded skin syndrome among neonates. J. Infect. 16(1), 87-103 (1988).
13. Patel GK, Varma S, Finlay AY. Staphyloccocal scalded skin syndrome in healthy adults. Br. J. Dermatol. 142(6), 1253-1255 (2000).
14. Johnston CA, Ghura HS, Carter E, Graham-Brown RA. Neonatal erythema multiforme major. Clin. Exp. Dermatol. 27(8), 661-4664 (2002).
15. Elias P, Fritsch P, Epstein E. Staphylococcal scalded skin syndrome. Arch. Dermatol. 113, 207-219 (1977).
16. Elias PM, Fritsch P, Epstein EH. Staphylococcal scalded skin syndrome. Clinical features, pathogenesis and recent microbiological and biochemical developments. Arch. Dermatol. 113(2), 207-219 (1977).
17. Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am. J. Clin. Dermatol. 4(3), 165-175 (2003).
18. Couppie P, Sainte-Marie D, Prevost G et al. Impetigo in French Guyana. A clinical, bacteriological, toxicological and sensitivity to antibiotics study. Ann. Dermatol. Venereol. 125(10), 688-693 (1998).
19. Rortveit S, Rortveit G. An epidemic of bullous impetigo in the municipality of Austevoll in the year 2002. Tidsskr Nor Laegeforen 123(18), 2557-2560 (2003).
20. McLinn S. Topical mupirocin versus systemic erythromycin treatment for pyoderma. Pediatr. Infect. Dis. J. 7(11), 785-790 (1988).
21. Bradley SF, Ramsey MA, Morton TM, Kauffman CA. Mupirocin resistance: clinical and molecular epidemiology. Infect. Cont. Hosp. Epidemiol. 16(6), 354-358 (1995).
22. Katz BE, Fisher AA. Bacitracin: a unique topical antibiotic sensitizer. J. Am. Acad. Dermatol. 17(6), 1016-1024 (1987).
23. Gollhausen R, Enders F, Przybilla B, Burg G, Ring J. Trends in allergic contact sensitization. Contact Dermatitis 18(3), 147-154 (1988).
24. Hedrick J. Acute bacterial skin infections in pediatric medicine: current issues in presentation and treatment. Paediatr. Drugs 5(Suppl. 1), 35-46 (2003).
25. Amaya-Tapia G, Aguirre-Avalos G, Andrade-Villanueva J et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. J. Antimicrob. Chemother. 31(Suppl. E), 129-135 (1993).
26. Feder HM Jr, Pond KE. Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections - an observation. Clin. Pediatr. (Phila) 35(4), 205-208 (1996).
27. Zafar AB, Butler RC, Reese DJ, Gaydos LA, Mennonna PA. Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery. Am. J. Infect. Cont. 23(3), 200-208 (1995).
28. Kauffman CA, Terpenning MS, He X et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term care facility with the use of mupirocin ointment. Am. J. Med. 94(4), 371-378 (1993).
29. Spicer WJ. Three strategies in the control of staphylococci including methicillin-resistant Staphylococcus aurues. J. Hosp. Infect 5(Suppl. A), 45-49 (1984).
30. Report of a combined working party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society and the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant Staphylococus aureus infection in hospitals. J. Hosp. Infect. 39, 253-290 (1998).
31. Kotra L, Samama J, Mobashery S. β-lactamases and resistance to β-lactam antibiotics. In: Bacterial Resistance to Antimicrobials. Lewis KS, Taber HW, Wax RG (Eds). Marcel Decker, NY, USA (2002).
32. Samaha-Kfoury J, Araj G. Recent developments in β-lactamases and extended spectrum β-lactamases. Br. Med. J. 1327, 1209-1213 (2003).
33. Duckworth G. Controlling methicillin resistant Staphylococcus aureus. Br. Med. J. 327(7425), 1177-1178 (2003).
34. Hryniewicz W. Epidemiology of MRSA. Infection 27(Suppl. 2), S13-S16 (1999).
35. Yamaguchi T, Yokota Y, Terajima J et al. Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. J. Infect. Dis. 185(10), 1511-1516 (2002).
36. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs 61(4), 525-551 (2001).
37. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34(11), 1481-1490 (2002).
38. Schweiger ES, Scheinfeld NS, Tischler HR, Weinberg JM. Linezolid and quinupristin/dalfopristin: novel antibiotics for Gram-positive infections of the skin. J. Drugs Dermatol. 2(4), 378-383 (2003).
39. Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J. Am. Acad.Dermatol. 50(3), 331-340 (2004).
40. Baggett HC, Hennessy TW, Leman R. An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect. Cont. Hosp. Epidemiol. 24(6), 397-402 (2003).
41. Al-Sulami AA, Al-Rubiay KK, Affat AM. An inhibitor of Staphylococcus aureus exfoliative toxin. East Mediterr. Health J. 7(1-2), 121-127 (2001).
42. Coyle EA. Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23(5), 638-642 (2003).
43. Ciftci E, Guriz H, Aysev AD. Mupirocin versus terbinafine in impetigo. Indian. J. Pediatr. 69(8), 679-682 (2002).